Technology
Health
Biotechnology

Pulmatrix

$0.888
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) As of 10:06 AM EDT today
$0.00 (0.00%) Today

Why Robinhood?

You can buy or sell Pulmatrix and other stocks, options, ETFs, and crypto commission-free!

About PULM

Pulmatrix, Inc. Common Stock, also called Pulmatrix, is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. Read More The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Employees
22
Headquarters
Lexington, Massachusetts
Founded
2015
Market Cap
7.20M
Price-Earnings Ratio
Dividend Yield
Average Volume
241.33K
High Today
$0.92
Low Today
$0.88
Open Price
$0.92
Volume
29.96K
52 Week High
$5.20
52 Week Low
$0.72

Collections

Technology
Health
Biotechnology
Medical
2015 IPO
US
North America

PULM Earnings

-$4.56
-$3.07
-$1.59
-$0.10
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.